Navigation Links
Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
Date:1/6/2011

SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the JP Morgan Healthcare Conference. The details are as follows: JP Morgan Healthcare ConferenceDate:  January 12, 2011Time:  9:30AM-10:00AM Pacific TimeLocation:  Westin St. Francis Hotel, San Francisco, CaliforniaSpeaker:  Mike Narachi, Chief Executive OfficerAbout Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity.  Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
4. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
6. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
7. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
8. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
9. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
10. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
11. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):